DBVT - DBV Technologies Announces Results of its 2024 Combined General Meeting | Benzinga
Châtillon, France, May 16, 2024
DBV Technologies Announces Results of its 2024 Combined General Meeting
Shareholders approved all proposed resolutions
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the "Company"), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
The Company's shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2024-annual-general-meeting/.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for ...